HRP20120657T1 - Farmaceutski pripravak 271 - Google Patents
Farmaceutski pripravak 271 Download PDFInfo
- Publication number
- HRP20120657T1 HRP20120657T1 HRP20120657AT HRP20120657T HRP20120657T1 HR P20120657 T1 HRP20120657 T1 HR P20120657T1 HR P20120657A T HRP20120657A T HR P20120657AT HR P20120657 T HRP20120657 T HR P20120657T HR P20120657 T1 HRP20120657 T1 HR P20120657T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- preparation according
- benzoimidazole
- phenylamino
- bromo
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 6
- 239000011159 matrix material Substances 0.000 claims abstract 15
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims abstract 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract 7
- WWWTWPXKLJTKPM-UHFFFAOYSA-N 2-aminooxyethanol Chemical compound NOCCO WWWTWPXKLJTKPM-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000005456 glyceride group Chemical group 0.000 claims abstract 6
- XAAPQRFIXGDKPZ-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-3-methylbenzimidazole-5-carboxylic acid Chemical compound OC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl XAAPQRFIXGDKPZ-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 21
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 14
- 238000002360 preparation method Methods 0.000 claims 11
- 239000007787 solid Substances 0.000 claims 10
- KWYWKYLYEIQRMF-UHFFFAOYSA-N CN1C(C=C(C(O)=O)C(NC(C=CC(Br)=C2)=C2Cl)=C2F)=C2N=C1.NOCCO Chemical compound CN1C(C=C(C(O)=O)C(NC(C=CC(Br)=C2)=C2Cl)=C2F)=C2N=C1.NOCCO KWYWKYLYEIQRMF-UHFFFAOYSA-N 0.000 claims 9
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 3
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- GRKFGZYYYYISDX-UHFFFAOYSA-N 6-(4-bromo-2-chloroanilino)-7-fluoro-n-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl GRKFGZYYYYISDX-UHFFFAOYSA-N 0.000 abstract 1
- 150000002334 glycols Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4037208P | 2008-03-28 | 2008-03-28 | |
| PCT/GB2009/050293 WO2009118562A1 (en) | 2008-03-28 | 2009-03-26 | Pharmaceutical composition 271 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120657T1 true HRP20120657T1 (hr) | 2012-09-30 |
Family
ID=40792932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120657AT HRP20120657T1 (hr) | 2008-03-28 | 2012-08-13 | Farmaceutski pripravak 271 |
Country Status (31)
| Country | Link |
|---|---|
| US (10) | US20090246274A1 (es) |
| EP (1) | EP2271321B1 (es) |
| JP (2) | JP5547710B2 (es) |
| KR (1) | KR101650958B1 (es) |
| CN (1) | CN102046156B (es) |
| AR (2) | AR071100A1 (es) |
| AU (1) | AU2009229204B2 (es) |
| BR (1) | BRPI0909267B8 (es) |
| CA (1) | CA2718653C (es) |
| CL (1) | CL2009000765A1 (es) |
| CO (1) | CO6311068A2 (es) |
| CY (1) | CY1113279T1 (es) |
| DK (1) | DK2271321T3 (es) |
| EC (1) | ECSP10010578A (es) |
| ES (1) | ES2387942T3 (es) |
| HK (2) | HK1149476A1 (es) |
| HR (1) | HRP20120657T1 (es) |
| IL (1) | IL208206A0 (es) |
| MX (1) | MX2010010671A (es) |
| MY (1) | MY157492A (es) |
| NZ (1) | NZ588849A (es) |
| PE (1) | PE20091755A1 (es) |
| PL (1) | PL2271321T3 (es) |
| PT (1) | PT2271321E (es) |
| RS (1) | RS52409B (es) |
| SA (1) | SA109300195B1 (es) |
| TW (1) | TWI433840B (es) |
| UA (1) | UA101654C2 (es) |
| UY (1) | UY31737A (es) |
| WO (1) | WO2009118562A1 (es) |
| ZA (1) | ZA201006766B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
| ES2654143T3 (es) | 2012-10-02 | 2018-02-12 | Gilead Sciences, Inc. | Inhibidores de desmetilasas de histonas |
| CN105263906B (zh) | 2013-02-27 | 2018-11-23 | 吉利德科学公司 | 组蛋白脱甲基酶的抑制剂 |
| EP3126345A1 (en) | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
| BR112017003442A2 (pt) | 2014-08-27 | 2017-11-28 | Gilead Sciences Inc | compostos e métodos para inibir histona desmetilases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022852A (en) | 1993-10-22 | 2000-02-08 | Hexal Ag | Pharmaceutical composition containing cyclosporin A |
| EP0754045B1 (en) | 1994-04-07 | 2002-03-06 | Smithkline Beecham Plc | compositions comprising halofantrine in a special form |
| EP0825849A1 (en) | 1995-05-19 | 1998-03-04 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| MY126358A (en) * | 1996-03-22 | 2006-09-29 | Glaxo Group Ltd | Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs |
| US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
| RU2211047C2 (ru) | 1997-01-30 | 2003-08-27 | Новартис Аг | Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел |
| US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
| US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| WO2004026235A2 (en) | 2002-09-20 | 2004-04-01 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| ES2549159T3 (es) | 2002-03-13 | 2015-10-23 | Array Biopharma, Inc. | Derivados de bencimidazol N3-alquilados como inhibidores de MEK |
| IL165383A0 (en) * | 2002-06-21 | 2006-01-15 | Transform Pharmaceuticals Inc | Pharmaceutical compositions with improved dissolution |
| US20040127551A1 (en) | 2002-12-27 | 2004-07-01 | Kai Zhang | Taxane-based compositions and methods of use |
| JP2007504266A (ja) * | 2003-09-02 | 2007-03-01 | ファイザー・プロダクツ・インク | ジプラシドンの持続放出剤形 |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| US20050096365A1 (en) | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
| AR046773A1 (es) | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| WO2005074890A1 (en) | 2004-01-30 | 2005-08-18 | Pfizer Italia S.R.L. | Semisolid matrix pharmaceutical formulations |
| KR20050104152A (ko) * | 2004-04-28 | 2005-11-02 | 최승호 | 경구용 약물의 흡수를 증진하는 약제학적 조성물 |
| US20070060610A1 (en) | 2005-06-16 | 2007-03-15 | Wempe Michael F | Methods and pharmaceutical formulations for increasing bioavailability |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| US9561178B2 (en) | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
| EP2268274B1 (en) | 2008-03-20 | 2012-05-16 | Virun, Inc. | Vitamin e derivatives and their uses |
| SA109300195B1 (ar) * | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
-
2009
- 2009-03-25 SA SA109300195A patent/SA109300195B1/ar unknown
- 2009-03-26 JP JP2011501300A patent/JP5547710B2/ja active Active
- 2009-03-26 WO PCT/GB2009/050293 patent/WO2009118562A1/en active Application Filing
- 2009-03-26 CN CN200980120227.7A patent/CN102046156B/zh active Active
- 2009-03-26 MX MX2010010671A patent/MX2010010671A/es active IP Right Grant
- 2009-03-26 US US12/411,865 patent/US20090246274A1/en not_active Abandoned
- 2009-03-26 RS RS20120357A patent/RS52409B/en unknown
- 2009-03-26 KR KR1020107023140A patent/KR101650958B1/ko active Protection Beyond IP Right Term
- 2009-03-26 DK DK09726304.0T patent/DK2271321T3/da active
- 2009-03-26 NZ NZ588849A patent/NZ588849A/en unknown
- 2009-03-26 CA CA2718653A patent/CA2718653C/en active Active
- 2009-03-26 BR BRPI0909267A patent/BRPI0909267B8/pt active IP Right Grant
- 2009-03-26 MY MYPI2010004504A patent/MY157492A/en unknown
- 2009-03-26 TW TW098109981A patent/TWI433840B/zh active
- 2009-03-26 UA UAA201012519A patent/UA101654C2/uk unknown
- 2009-03-26 ES ES09726304T patent/ES2387942T3/es active Active
- 2009-03-26 AU AU2009229204A patent/AU2009229204B2/en active Active
- 2009-03-26 PL PL09726304T patent/PL2271321T3/pl unknown
- 2009-03-26 PT PT09726304T patent/PT2271321E/pt unknown
- 2009-03-26 EP EP09726304A patent/EP2271321B1/en active Active
- 2009-03-26 UY UY0001031737A patent/UY31737A/es not_active Application Discontinuation
- 2009-03-27 AR ARP090101107A patent/AR071100A1/es not_active Application Discontinuation
- 2009-03-27 CL CL2009000765A patent/CL2009000765A1/es unknown
- 2009-03-27 PE PE2009000461A patent/PE20091755A1/es not_active Application Discontinuation
-
2010
- 2010-09-16 IL IL208206A patent/IL208206A0/en active IP Right Grant
- 2010-09-21 ZA ZA2010/06766A patent/ZA201006766B/en unknown
- 2010-10-28 EC EC2010010578A patent/ECSP10010578A/es unknown
- 2010-10-28 CO CO10134209A patent/CO6311068A2/es active IP Right Grant
-
2011
- 2011-04-06 HK HK11103478.2A patent/HK1149476A1/xx unknown
- 2011-10-18 HK HK11111114.5A patent/HK1156844A1/xx unknown
- 2011-11-10 US US13/293,368 patent/US20120114750A1/en not_active Abandoned
-
2012
- 2012-08-13 HR HRP20120657AT patent/HRP20120657T1/hr unknown
- 2012-08-13 CY CY20121100732T patent/CY1113279T1/el unknown
-
2013
- 2013-01-23 US US13/747,853 patent/US20130195971A1/en not_active Abandoned
-
2014
- 2014-02-17 JP JP2014027398A patent/JP2014114320A/ja active Pending
-
2015
- 2015-10-15 US US14/884,343 patent/US20160030574A1/en not_active Abandoned
-
2016
- 2016-11-10 US US15/348,053 patent/US20170056375A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/023,102 patent/US20190030004A1/en not_active Abandoned
-
2019
- 2019-08-23 AR ARP190102398A patent/AR116001A2/es not_active Application Discontinuation
- 2019-10-09 US US16/597,237 patent/US20200179344A1/en not_active Abandoned
-
2021
- 2021-05-06 US US17/313,312 patent/US11813246B2/en active Active
-
2023
- 2023-10-10 US US18/484,337 patent/US20240041835A1/en active Pending
- 2023-10-10 US US18/484,334 patent/US20240041834A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120657T1 (hr) | Farmaceutski pripravak 271 | |
| CN102614091B (zh) | 白藜芦醇纳米结构脂质载体及其制备方法 | |
| CN101658468B (zh) | 辅酶q纳米结构脂质载体及其制备方法 | |
| CN105899491A (zh) | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 | |
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| MX354328B (es) | Formulacion mixta que comprende tableta esferoidal de unidades multiples encapsuladas en capsula dura y metodo para preparar la misma. | |
| HRP20201048T1 (hr) | Farmaceutska formulacija koja sadrži inozitol | |
| JP2012236834A5 (es) | ||
| RU2014129508A (ru) | Новая комбинация | |
| JP2013517304A5 (es) | ||
| ITMI20072051A1 (it) | Composizione a base di pellet di acido lipoico | |
| CN103830201A (zh) | 一种度他雄胺液体软胶囊 | |
| CN105452258A (zh) | 使用双核金(i)化合物用于癌症治疗的方法 | |
| ES2761868T3 (es) | Cápsula blanda de 2,2,6,6-tetraisopropil-4,4-2-bifenol y método para la preparación de la misma | |
| Geronimo et al. | Development of S 75: R 25 bupivacaine‐loaded lipid nanoparticles functionalized with essential oils for treating melanoma | |
| Parveen et al. | RETRACTED ARTICLE: Investigation of Eutectic Mixtures of Fatty Acids as a Novel Construct for Temperature-Responsive Drug Delivery | |
| CN104473910A (zh) | 一种普瑞巴林缓释微丸及其制备方法 | |
| HRP20210236T1 (hr) | Formulacije zadržanog otpuštanja lorazepama | |
| Li et al. | Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer | |
| CN102886047A (zh) | 黄芩素组合物及其制备方法 | |
| CN105581935B (zh) | 紫檀芪亚微米脂质粒及其制备方法 | |
| CN102166270A (zh) | 一种水包油型陈皮油纳米乳及其制备方法 | |
| ITMI20010220A1 (it) | Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno | |
| CN102283954A (zh) | 一种猪苓汤整合型新剂型制备技术及其生产方法 | |
| PH12014502609B1 (en) | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug |